The Society for Immunotherapy of Cancer (SITC) invites you to submit abstracts containing new data for consideration as a Late-breaking Abstract – Clinical Only (LBA) for oral and/or poster abstract presentation at SITC 2024, the leading cancer immunotherapy and immunology conference. Late-breaking Abstract submissions are open through Sept. 12 at 5 p.m. PDT.

LBA submission is solely for abstracts with late-breaking data from interventional clinical trials in humans and not for abstracts submitted “late.” The LBA deadline is not intended to be an extension of the general submission deadline. LBAs highlight novel and practice-changing in-human clinical studies and only apply to data that would have not otherwise have been presented as an abstract at the 39th Annual Meeting.

New in 2024: Late-Breaking Abstracts - Clinical Only
LBAs must address interventional clinical trials in humans. LBAs addressing basic science or translational data with no in-human studies will not be accepted. LBAs may contain data from preclinical studies, but they must also include clinical data from in-human trials. Authors will need to justify why the abstract is considered late-breaking. Clinical trial LBAs should be submitted during the LBA submission period, from July 15–Sept. 12 at 5 p.m. PDT.

Submit your abstract by Sept. 12 at 5 p.m. PDT: https://www.sitcancer.org/2024/abstra...